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ABSTRACT
Rationale: Severe acute asthma (SAA) can be fatal, but is often preventable. We previously observed in a
retrospective cohort study, a three-fold increase in SAA paediatric intensive care (PICU) admissions
between 2003 and 2013 in the Netherlands, with a significant increase during those years of numbers of
children without treatment of inhaled corticosteroids (ICS).
Objectives: To determine whether steroid-naïve children are at higher risk of PICU admission among
those hospitalised for SAA. Furthermore, we included the secondary risk factors tobacco smoke exposure,
allergic sensitisation, previous admissions and viral infections.
Methods: A prospective, nationwide multicentre study of children with SAA (2–18 years) admitted to all
Dutch PICUs and four general wards between 2016 and 2018. Potential risk factors for PICU admission
were assessed using logistic regression analyses.
Measurements and main results: 110 PICU and 111 general ward patients were included. The proportion
of steroid-naïve children did not differ significantly between PICU and ward patients. PICU children were
significantly older and more exposed to tobacco smoke, with symptoms >1 week prior to admission. Viral
susceptibility was not a significant risk factor for PICU admission.
Conclusions: Children with SAA admitted to a PICU were comparable to those admitted to a general
ward with respect to ICS treatment prior to admission. Preventable risk factors for PICU admission were
>7 days of symptoms without adjustment of therapy and exposure to tobacco smoke. Physicians who treat
children with asthma must be aware of these risk factors.
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Severe acute asthma (SAA; status asthmaticus) is a severe and potentially fatal asthma exacerbation that
does not respond to standard treatment with bronchodilators and systemic corticosteroids [1]. Every child
with asthma is at risk of SAA, even those with mild asthma [2, 3]. Admission to a paediatric intensive care
unit (PICU) occurs in 5–34% of all asthma hospitalisations [4–7]. Worldwide, the number of children
requiring PICU admission increased markedly in the past decade, while the prevalence of asthma in
children did not [4, 5, 8, 9]. Previously, we showed a three-fold increase of children with SAA admitted to
Dutch PICUs between 2003 and 2013, with a significant increase over the years in the proportion of
steroid-naïve children [9].
New asthma guidelines [10] advise clinicians to look for key triggers that put patients at an increased risk of an
exacerbation [11]. Multiple studies have focused on risk factors for PICU admission, with different outcomes.
Those risk factors included inhaled corticosteroids (ICS) use [2, 7, 12], longer asthma duration [13], sex [7, 12],
ethnicity [2], previous emergency department visits [13] or (PICU) hospitalisations [2, 14, 16–], sensitisation
to (multiple) aeroallergens [13, 15] and exposure to environmental tobacco smoke (ETS) [14].
In contrast to the above studies, we included all these risk factors in this multicentre (including all Dutch
PICUs) prospective study. Identifying risk factors offers the opportunity for early intervention to avoid
PICU admission of children with SAA. Since daily ICS is the most effective treatment to reduce asthma
symptoms and prevent exacerbations [1, 17–20], we hypothesised that children without daily ICS are more
prone to SAA requiring PICU admission. In addition, we looked into other risk factors such as ETS, viral
infections, lower socioeconomic status (SES), sensitisation to (multiple) aeroallergens, and previous
asthma-related healthcare visits.
Methods
We prospectively identified all children (aged 2–18 years) with SAA admitted to all seven Dutch academic
PICUs or one of the paediatric wards of four participating general hospitals between 2016 and 2018. The
four general hospitals were recruited based on geographical distribution over the Netherlands and needed
to have a staff paediatric pulmonologist. Furthermore, these hospitals were good examples of general
hospitals in the Netherlands, enhancing the external validity of the study. We included children aged
⩾2 years, since SAA treatment is the same for children across all age ranges in the Netherlands. For each
group (PICU and general ward), patients were recruited until the pre-planned sample size of 110 patients
per group had been achieved. SAA was defined as a doctor-diagnosed asthma exacerbation requiring
systemic corticosteroids and hospital admission. According to Dutch national guidelines, all children
receive the same initial treatment: oxygen, continuous inhalation with salbutamol plus ipratropium and
systemic corticosteroids [21]. When the asthma score, as developed by QURESHI et al. [22], is still ⩾10 after
three consecutive nebulisations with salbutamol plus ipratropium an intravenous magnesium sulphate
bolus is administered. If continued nebulisation and i.v. magnesium sulphate lead to insufficient response,
continuous infusion with salbutamol is started. When i.v. salbutamol is administered, children are
transferred to a PICU, regardless of the dosage. Evidence indicates that this protocol is well followed in the
Netherlands [9]. A child was classified as steroid-naïve when there was no maintenance treatment with
ICS for >7 days before admission. The highest educational level of the parents and the postal code were
used to determine SES. Ethnicity was defined as Caucasian or non-Caucasian. The severity of the
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exacerbation at the time of admission was classified using the Asthma Score. Additional details on the
definition of SES, ethnicity and the Dutch guidelines for PICU admission are provided in the
supplementary material.
Adherence to ICS was expressed as the proportion of days covered (PDC) in the period preceding the
index admission [23], according to the pharmacy records. Continuous and categorical measures of ICS
adherence were used. For the categorical measures a PDC of <80% (non-adherent) or a PDC ⩾80%
(adherent) were used. The cut-off values were chosen based on previous studies [24, 25].
We assessed a radioallergosorbent test for inhaled allergens in all children unless performed within the
previous year. From every child, we acquired a nasal swab within 24 h after admission. The nasal swab was
examined using real-time reverse transcriptase (RT)-PCR for the detection of viruses [26].
We determined urinary cotinine within 6 h after admission, as a proxy for ETS [27]. A value of
<10 ng·mL−1 was interpreted as no recent ETS exposure; a value of 10–100 ng·mL−1 as second-hand
smoke exposure; and a value >200 ng·mL−1 as active smoking [28].
A blood sample for DNA analysis was only collected if blood was drawn for standard care measurements.
DNA was isolated from 200 μL of whole blood. Single nucleotide polymorphisms (SNPs) in the ADRβ2 at
position 16 (rs1042713) and 27 (rs1042714), and SNPs in the CDHR3 (rs6967330) were characterised [29].
Further details on the methods for medication adherence and viral detection are provided in the
supplementary material. Information about patient history, SES and environmental triggers was obtained
from patients and caregivers using a web-based questionnaire, using LimeSurvey (version 2.06lts; www.
limesurvey.org/).
Analyses
Data are presented as mean±SD or median (interquartile range). The Chi-squared test was used to compare
categorical variables between both groups, and the Mann–Whitney test was used for continuous variables.
Multivariate analysis was performed using multiple logistic regression analysis to evaluate the relationship
between covariates and the probability of PICU admission.
Covariates were chosen based on the univariate analysis. Additional details on the sample size calculation
and analyses are provided in the supplementary material. Given the potential difference in risk factors and




Not able to speak and write in Dutch n=24
No asthma diagnosis  n=8
Previously enrolled into the study n=6
Tracheobronchomalacia  n=3
No prednisone   n=3
Congenital/acquired heart disease n=2
Bronchopulmonary dysplasia  n=2
Primary immunodeficiency  n=1
Logistic reasons   n=164









FIGURE 1 Flowchart of study enrolment. SAA: severe acute asthma; PICU: paediatric intensive care unit.
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diagnosis, a pre-planned subgroup analysis was performed for preschoolers (aged 2–4 years) versus
school-aged children (aged 5–17 years). Statistical analyses were performed using SPSS (version 25;
Chicago, IL, USA), and a two-sided significance level of 0.05 was used. Informed written consent was
obtained before participation. The study was approved by the research ethics committee of the Erasmus
Medical Center Rotterdam (MEC 2015–709) and adopted by the other hospitals.
Results
221 children were recruited into the study: 110 were admitted to the PICU and 111 to the general ward
(figure 1). Table 1 shows their baseline characteristics.
Asthma was diagnosed before admission in 76% of the children admitted to the PICU and in 71% of the
children admitted to the general ward. The proportion of steroid-naïve children, with or without a
previous asthma diagnosis, did not differ significantly between PICU and general ward. Children admitted
to the PICU were significantly older. Other significant factors associated with increased odds of PICU
admission included being non-Caucasian, ICS adherence, asthma symptoms >1 week prior to admission
and previous PICU admission (table 2). Two children died at the PICU of hypoxic ischaemic
encephalopathy following out-of-hospital cardiac arrest, most likely due to patient delay and anaphylaxis.
The presence of human rhinovirus (HRV), or other viruses, was not a risk factor for PICU admission
(table 3).
Table 4 shows presentation and in-hospital management. The asthma severity scores (Qureshi score) at
admission were comparable between groups.
Multiple logistic regression analysis revealed that a PICU admission was significantly more likely in children
who were older, had had symptoms >1 week prior to admission and were exposed to ETS (table 5).
Preschool children admitted to a PICU were less often treated by a paediatric pulmonologist prior to
admission than children in the general ward group (supplementary table S1).
In school-aged children, significant factors associated with increased odds of PICU admission included
being non-Caucasian, an older age, presence of symptoms >1 week prior to admission, and high urinary
cotinine (all p-values <0.017; supplementary table S2). In multiple logistic regression analysis, an older age,
TABLE 1 Baseline characteristics
PICU Paediatric ward p-value
Subjects 110 111
Age years 110 8 (5–12) 111 5 (3–7) <0.001
Preschoolers (age 2–4 years) 110 27 (25) 111 55 (50) <0.001
Male 110 68 (62) 111 69 (62) 0.958
Caucasian 110 60 (55) 111 79 (71) 0.011
Asthma diagnosis prior to admission 110 84 (76) 111 79 (71) 0.380
Asthma treated by# 0.370
General practitioner 82 29 (35) 77 28 (36)
Paediatrician 82 31 (38) 77 22 (29)
Paediatric pulmonologist 82 22 (27) 77 27 (35)
Steroid naïve 110 56 (51) 111 67 (60) 0.157
ICS dose¶ μg 52 323±181 44 224±102 0.001
Adherence to ICS¶
PDC % 52 73±33 43 62±30 0.114
PDC ⩾80% 52 30 (58) 43 16 (37) 0.047
Born <37 weeks’ gestational age 84 13 (15) 84 15 (18) 0.679
Highest parental education level 0.390
Low 82 3 (4) 84 1 (1)
Middle 82 35 (43) 84 31 (37)
High 82 44 (54) 84 52 (62)
SES scores+ 110 −0.29±1.36 111 −0.25±1.28 0.824
Data are presented as n, median (interquartile range), n (%) or mean±SD, unless otherwise stated. Bold
type represents statistical significance. PICU: paediatric intensive care unit; ICS: inhaled corticosteroids;
PDC: proportion of days covered; SES: socioeconomic status. #: children with a diagnosis of asthma prior
to admission. ¶: of the children with prescribed ICS. +: the postal code was used to quantify the
neighbourhood SES, with a mean of zero. A lower (negative) score is associated with a lower SES.
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symptoms >1 week prior to admission and elevated cotinine remained statistically significant predictors of
PICU admission (supplementary table S3).
Discussion
In this nationwide multicentre prospective study, we found no significant difference in the proportion of
steroid-naïve children with SAA admitted to a PICU or a general ward. In general, PICU children were
older, more exposed to tobacco smoke and had a longer duration of asthma symptoms before admission.
Daily ICS or ICS as rescue medication with a short-acting β-agonist (SABA) protects against asthma
exacerbations compared to SABA alone [17, 30], but uncontrolled asthma is not rare [31], even in children
TABLE 2 Asthma severity
PICU Paediatric ward p-value
Subjects 110 111
Medication step prior to admission# 0.076
Step 1 110 31 (28) 111 42 (38)
Step 2 110 12 (11) 111 10 (9)
Step 3 110 18 (16) 111 24 (22)
Step 4 110 24 (22) 111 10 (9)
Step 5 110 111
No medication 110 25 (23) 111 25 (23)
Symptoms >1 week prior to admission 108 60 (55) 109 25 (23) <0.001
Prior hospital admissions
Non-PICU 106 64 (60) 97 69 (71) 0.107
Ever to PICU 110 15 (14) 111 6 (5) 0.037
Admission in previous year 108 32 (30) 111 30 (27) 0.669
Emergency department visits previous year 0.022
None 84 38 (45) 84 21 (25)
1–3 84 41 (49) 84 57 (68)
>3 84 5 (6) 84 6 (7)
Prednisolone course in the previous year 84 56 (67) 84 71 (85) 0.007
Data are presented as n or n (%), unless otherwise stated. Bold type represents statistical significance.
PICU: paediatric intensive care unit. #: according to the Global Initiative for Asthma [1].
TABLE 3 Atopy and environmental triggers
PICU Paediatric ward p-value
Subjects 110 111
Allergic sensitisation# 103 79 (77) 110 71 (65) 0.052
Multiple sensitisation¶ 102 24 (24) 110 15 (14) 0.063
Food allergies 56 22 (39) 53 7 (13) NA
Respiratory viral infections
PCR positive for ⩾1 virus 102 56 (55) 104 65 (63) 0.268
PCR positive for ⩾2 viruses 102 7 (7) 104 14 (13) 0.191
Symptoms and PCR positive 98 44 (45) 103 53 (52) 0.352
PCR positive for rhinovirus 102 42 (41) 104 56 (54) 0.069
Rhinovirus A 22 10 (46) 33 17 (52) 0.448
Rhinovirus B 22 1 (5) 33 0
Rhinovirus C 22 11 (50) 33 16 (49)
Parental self-reported smoking 103 28 (27) 108 26 (24) 0.812
Urinary cotinine 0.150
Nonsmoker <10 ng·mL−1 96 74 (77) 89 77 (87)
Passive smoker >10 ng·mL−1 96 20 (21) 89 12 (13)
Active smoker >200 ng·mL−1 96 2 (2) 89
Siblings >2 84 25 (30) 84 26 (31) 0.867
Data are presented as n or n (%), unless otherwise stated. PICU: paediatric intensive care unit; NA: not
available. #: positive radioallergosorbent test (RAST) = IgE >0.7 kU·L−1 for at least one of the allergens;
¶: positive RAST for at least one pet, pollen and house dust mite.
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with daily ICS, and was a risk factor for PICU admission in some studies [2, 7]. This might be due to the
fact that children using ICS had persistent and more severe asthma and consequently a higher risk for
SAA and PICU admission. This theory is supported by the fact that children admitted to the PICU had a
significantly higher ICS dose prior to admission. In our study, risk factors for PICU admission seem to be
driven by host (age, ethnic background and patient delay) and environmental (exposure to ETS)
characteristics, rather than ICS use only. Targeted strategies aimed at the prevention of severe asthma
exacerbations, even despite treatment with daily ICS, are needed. Strategies such as enhancing awareness in
the general population of symptoms of asthma or uncontrolled asthma may empower the general public to
seek medical help earlier than some parents in this study. The risk of children having dangerous asthma
exacerbations as a result of cigarette smoke exposure is yet another clear effect of cigarette smoke exposure
that legislatures need to take into account in smoke-free policies.
TABLE 4 Presentation and in-hospital management
PICU Paediatric ward p-value
Subjects 110 111
pH# 102 7.34±0.1 Not done
PCO2 kPa
# 102 5.5±1.8 Not done
Asthma severity score (Qureshi) 0.439
Mild 105 6 (6) 106 9 (8)
Moderate 105 50 (48) 106 56 (53)
Severe 105 49 (47) 106 41 (39)
Acute asthma treatment
Inhaled short-acting β-agonist 110 108 (98) 111 111 (100) 0.154
Systemic corticosteroids 110 109 (99) 111 110 (99) 0.995
Antibiotics 110 45 (41) 110 18 (16) <0.001
Intravenous magnesium 110 108 (98) 111 16 (14) <0.001
Intravenous salbutamol 110 109 (99) 111 0 <0.001
Ketamine 110 12 (11) 111 0 <0.001
Theophylline 110 7 (6) 111 0 <0.001
Maximal respiratory support <0.001
None 110 1 (1) 111 26 (23)
Nasal cannula 110 15 (14) 111 71 (64)
Non-rebreathing mask 110 34 (31) 111 14 (13)
High-flow nasal cannula 110 46 (42) 111
Noninvasive ventilation 110 1 (1) 111
Invasive mechanical ventilation 110 13 (12) 111
Disposition
Sent home 110 108 (98) 111 111 (100)
Died in the hospital 110 2 (2) 111 0
Hospital length of stay days 107 6.3±2.3 111 3.2±1.2 <0.001
Data are presented as n, mean±SD or n (%), unless otherwise stated. Bold type represents statistical
significance. PICU: paediatric intensive care unit; PCO2: carbon dioxide tension.
#: determined in a capillary
blood sample.
TABLE 5 Multiple logistic regression analysis of risk factors for paediatric intensive care unit
(PICU) admission
OR (95% CI) p-value
Steroid naïve 1.144 (0.575–2.276) 0.702
Age in years# 1.263 (1.141–1.399) <0.001
Female 1.407 (0.722–2.745) 0.316
Caucasian 0.532 (0.273–1.039) 0.064
Respiratory viral infection 1.207 (0.601–2.424) 0.597
Symptoms >1 week prior to admission 4.252 (2.130–8.489) <0.001
Previous PICU admissions 2.785 (0.873–8.879) 0.083
Positive urinary cotinine >10 ng·mL−1 3.733 (1.442–9.659) 0.007
Bold type represents statistical significance. #: continuous variable.
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The most important risk factor for PICU admission was having symptoms for >1 week prior to admission.
These children were significantly older (median age 8 years versus 6 years). Only 30% of the children with
symptoms for >1 week prior to admission received oral corticosteroids (OCS) before arrival at the
emergency department. Patient and doctor delay contributed to a longer duration of symptoms followed
by a more severe attack. Early treatment with OCS in these children could have possibly prevented
hospitalisation or PICU admission. Hospital admission produces a high level of stress on the child and
caregivers, especially at the PICU. Furthermore, bed availability and the high medical costs emphasise the
need for a more vigilant approach if symptoms persist to prevent PICU admission.
The age difference between the PICU and general ward group could be due to the fact that these groups
represent different disease categories. STEIN and MARTINEZ [32] have shown that asthma phenotypes are
markedly heterogeneous in the first 6 years of life. In fact, some of these phenotypes are transient and
seem to behave idiosyncratically.
In agreement with previous studies, exposure to ETS was significantly associated with a higher frequency of
PICU admission [2] or emergency department management failure [33]. In the PICU population, children
with ETS-associated SAA deteriorated and recovered more slowly than non-ETS-exposed children [34].
Additional to previous studies we used urinary cotinine to quantify and identify ETS as an objective risk
factor for PICU admission among children hospitalised for SAA. Caregivers should be made aware that
ETS confers a four-fold increased risk for PICU admission in case of SAA, and offered appropriate support
to stop smoking. Preferably, any financial obstacles should be reimbursed.
Our data corroborate previous studies reporting that the majority of children requiring hospital admission
were allergically sensitised and had at least one viral respiratory infection identified, mostly due to
rhinovirus [2, 13, 15, 35–38]. In our study, HRV-C was not a risk factor for PICU admission among
children hospitalised for asthma. Although we found a high HRV-C prevalence, in itself it may be a risk
factor for hospitalisation, but not differentiate in terms of severity beyond that point.
Children with SAA admitted to Dutch PICUs have a relatively short PICU stay compared with the general
PICU population. According to the Dutch paediatric guideline for SAA [21], continuous i.v.
administration of salbutamol requires immediate transfer to a PICU, regardless of the dosage. Hence,
children in our study might have had less severe illness than asthmatic children in other PICU studies, as
suggested by the low numbers of children requiring invasive mechanical ventilation and low mortality [2].
Of the children admitted to the PICU, 24% were first presentations. Hence in these children a PICU
admission could not easily have been prevented except for education of the general public on asthma
symptoms.
In addition, we looked at the effect of polymorphisms of the ADRβ2 and CDHR3 asthma risk alleles, since
the ADRβ2 gene might reduce bronchodilator responsiveness in asthmatic children [39], and the CDHR3
asthma risk allele is associated with more severe HRV-C-induced asthma attacks [40]. In our study,
genotyping of the ADRβ2 at position 16 (rs1042713) and 27 (rs1042714), and the CDHR3 asthma risk
allele (rs6967330) showed no significant differences between PICU and general ward (data not shown).
However, our study was not powered to detect a difference.
Limitations/strengths
Strengths of the present study are a high inclusion rate of 75% of children admitted to all Dutch PICUs,
with standardised criteria for PICU admission. We investigated multiple potential risk factors, including
objective measures such as cotinine in the urine for exposure to ETS, RT-PCR for viral infections, and use
of asthma medication based on pharmacy records. There are some limitations as well. First, asthma was
defined as diagnosed by a paediatrician prior to or during the exacerbation. The diagnosis was reviewed by
a paediatric pulmonologist at the follow-up visits. We are well aware that asthma may be undistinguishable
from acute viral wheeze in children aged <6 years; however, this will not affect treatment decisions in the
setting of SAA. All children were seen by a paediatric pulmonologist during follow-up and 90% still used
asthma medication after 3–9 months (the remaining 10% were lost to follow-up), which supports that the
initial asthma diagnosis was correct. Second, data regarding lung function at time of presentation to the
emergency department are lacking. Only 20 (18%) children in the PICU group had performed lung
function testing recently: 13 children had airflow obstruction, nine children had forced expiratory volume
in 1 s (FEV1) <80%. In the general ward group, 10 (9%) children performed a lung function test prior to
admission: three children had airflow obstruction, with a FEV1 <80% in one child. Third, we used the
PDC in the period preceding the index admission as a proxy for ICS treatment. Although the PDC is an
objective measurement, this is not equivalent to the actual use of medication or good inhalation technique.
Lastly, 30% of DNA analysis is missing in the general ward group because blood samples were only
collected if blood was drawn for routine care measurements.
https://doi.org/10.1183/23120541.00126-2020 7
ASTHMA | S.A. BOESCHOTEN ET AL.
Conclusion
We found no significant differences in the proportion of steroid-naïve children between children with SAA
admitted to the PICU versus those admitted to a general ward. Prolonged duration of symptoms prior to
admission and environmental tobacco smoke exposure were clinically relevant strong risk factors for PICU
admission. These are preventable triggers and our data clearly support the call for smoking cessation by
caretakers of children. We recommend a rapid and vigilant approach for children with prolonged asthma
symptoms as they are at high risk for PICU admission for SAA.
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